superantibody

superantibody

An antibody that has been chemically modified so that it is capable of binding to an antigen within a cell rather than on a cell surface. Superantibodies are thought to have potential for new forms of treatment.
References in periodicals archive ?
VANCOUVER, British Columbia -- InNexus Biotechnology (TSX VENTURE:IXS) (OTCBB:IXSBF) today announced that it has entered into a technology collaboration agreement to evaluate the use of InNexus' SuperAntibody Technology in combination with an antibody for the treatment of certain viral infections.
The funding will be used to advance the completion of one or more monetized partnerships for InNexus' SuperAntibody Technology and initiate development of a lead SuperAntibody therapeutic candidate.
V: IXS)(OTCBB: IXSBF) and Affimed Therapeutics today announced a collaboration utilizing Affimed's antibodies and InNexus' SuperAntibody antibody enhancement drug development platform.
TSX: IXS)(OTCBB: IXSBF), an innovative antibody-driven drug development company based on SuperAntibody(TM) Technologies, today announced an expansion to its product development strategy with the introduction of its SuperAntibody Bioequivalent program.
InNexus will be presenting on Thursday, October 28, 2004 at 9:25 AM EDT and will be describing its SuperAntibody Technology Platform and its first potential SuperAntibody Product, S(T15), for treating plaque in Coronary Heart Disease.
Heinz Kohler, inventor of SuperAntibody technology and head of research at InNexus, enthusiastically stated "we sought to prove we could use SAT to enhance the potency of a humanized antibody for killing human cancer cells, which we achieved.
the "Company") announced today the scientific publication and disclosure of a monoclonal-antibody-based, delivery system for intracellular targets utilizing SuperAntibody technology ("SAT").
This discovery has enabled InNexus to file an additional patent that protects more uses of SuperAntibody Technology ("SAT") and will ultimately allow InNexus to work with more corporate partners.
The companies will develop lead antibody candidates combining InNexus' SuperAntibody Technology (SAT) with up to four antibodies from Corixa's therapeutic antibody development program.
Utilizing SAT, 1F7 will be converted into a SuperAntibody for clinical development.
SuperAntibody technology ("SAT") is the next-generation technology platform for monoclonal antibodies, able to increase their strength of binding and allow them to cross-link their target antigen.
OTCBB:IMMKF)(CDNX:IMM) announced today it has granted a sublicense option to InNexus Corporation of Seattle for the application of SuperAntibody technology to Immune Network's monoclonal antibodies hNM01 and 1F7.